The octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegaly

European Journal of Endocrinology

Volumn 154, Issue 2, 2006, Pages 267-274

  Pokrajac, Ana ^a   Claridge, Andrew G ^a   Abdul Shakoor, S K ^a   Trainer, Peter J ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GROWTH HORMONE BLOOD LEVEL; HORMONE RESPONSE; HUMAN; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY;

ACROMEGALY; ADULT; AGED; AGED, 80 AND OVER; DIAGNOSTIC TESTS, ROUTINE; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC;

EID: 33644595579     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02073     Document Type: Article

References (23)

1. Plewe G, Beyer J, Krause U, Neufeld M & Del Pozo E. Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly. Lancet 1984 2 (8406) 782-784.
2. Lamberts SWJ, Van der Lely AJ, Herder WW & Hofland LJ. Octreotide. New England Journal of Medicine 1996 334 246-254.
3. Stewart PM, Kane KF, Stewart SE, Lancranjan I & Sheppard MC. Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. Journal of Clinical Endocrinology and Metabolism 1995 80 3267-3272.
4. Freda PU. Somatostatin analogues in acromegaly. Journal of Clinical Endocrinology and Metabolism 2002 87 3013-3018.
5. Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, James RA, McConnell M, Roberts GA, Scanlon MF, Stewart PM, Teasdale E, Turner HE, Wass JAH & Wardlaw JM. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. Journal of Clinical Endocrinology and Metabolism 2002 87 4554-4563.
6. Heron I, Thomas F, Dero M, Gancel A, Ruiz JM, Schatz B & Kuhn JM. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 1993 76 721-727.
7. Attanasio R, Baldelli R, Pivonello R, Grottoli S, Bocca L, Gasco V, Giusti M, Tamburrano G, Colao A & Cozzi R. Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. Journal of Clinical Endocrinology and Metabolism 2003 88 5258-5265.
8. Reubi JC & Landolt AM. The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status. Journal of Clinical Endocrinology and Metabolism 1989 68 844-850.
9. Kaltsas GA, Isidori AM, Florakis D, Trainer PJ, Camacho-Hubner C, Afshar C, Sabin I, Jenkins JP, Chew SL, Monson JP, Besser GM & Grossman AB. Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity. Journal of Clinical Endocrinology and Metabolism 2001 86 1645-1652.
10. Brabant G, Von zur Muhlen A, Wuster C, Ranke MB, Kratzsch J, Kiess W, Ketelslegers JM, Wilhelmsen L, Hulthen L, Saller B, Mattsson A, Wilde J, Schemer R, Kann P & German KIMS Board. Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study. Hormone Research 2003 60 53-60.
11. Flogstad AK, Halse J, Bakke S, Lancranjan I, Marbach P, Bruns CH & Jervell J. Sandostatin LAR in acromegalic patients: long term treatment. Journal of Clinical Endocrinology and Metabolism 1997 82 23-28.
12. Lancranjan I & Atkinson AB. Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group. Pituitary 1999 1 105-114.
13. Ezzat S, Redelmeier DA, Gnhelm M & Harris AG. A prospective multicenter octreotide dose response study in the treatment of acromegaly. Journal of Endocrinological Investigation 1999 18 364-369.
14. Pieters GFFM, Smals AGH & Kloppenborg PWC. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995 [Letter]. New England Journal of Medicine 1986 314 1391.
15. Lamberts SW, Uitterlinden P & Del Pozo E. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years. Journal of Clinical Endocrinology and Metabolism 1987 65 703-710.
16. Lamberts SW, Uitterlinden P, Schuijff PC & Klijn JG. Therapy of acromegaly with sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical 'cure'. Clinical Endocrinology (Oxford) 1988 29 411-420.
17. Colao A, Ferone D, Lastoria S, Marzullo P, Cerbone G, Di Sarno A, Longobardi S, Merola B, Salvatore M & Lombardi G. Prediction of efficacy of octreotide therapy in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism 1996 81 2356-2362.
18. Karavitaki N, Botusan I, Radian S, Coculescu M, Turner HE & Wass JAH. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. Clinical Endocrinology (Oxford) 2005 62 282-288.
19. Biermasz NR, Pereira AM, Smit JW, Romijn JA & Roelfsema F. Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly. Growth Hormone and IGF Research 2005 15 200-206.
20. Gilbert JA, Miell JP, Chambers SM, McGregor AM & Aylwin SJ. The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of Somatostatin analogue therapy in acromegaly. Clinical Endocrinology (Oxford) 2005 62 742-747.
21. De Herder WW, Taal HR, Uitterlinden P, Feelderrs RA, Janssen J & van der Lely AJ. Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly. European Journal of Endocrinology 2005 153 67-71.
22. Bates AS, Van't Hoff W, Jones JM & Clayton PE. An audit of outcome of treatment in acromegaly. Quarterly Journal of Medicine 1993 86 293-299.
23. Orme SM, McNally RJ & Cartwright PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. Journal of Clinical Endocrinology and Metabolism 1998 83 2730-2734.